Pharmaceuticals in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in the Netherlands
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in the Netherlands
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands pharmaceuticals market with five year forecasts
Essential resource for top-line data and analysis covering the Netherlands pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Reasons To Buy
What was the size of the Netherlands pharmaceuticals market by value in 2015?
What will be the size of the Netherlands pharmaceuticals market in 2020?
What factors are affecting the strength of competition in the Netherlands pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitors in the Netherlands's pharmaceuticals market?
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2015 annual average exchange rates.
The Dutch pharmaceuticals market had total revenues of $5.0bn in 2015, representing a compound annual rate of change (CARC) of -1.2% between 2011 and 2015.
The Dutch ‘preference policy’ sets out how, if possible, there is a preference for prescribing a cheaper version of a medicine, provided it has the same efficacy as the brand-name medicine.
The performance of the market is forecast to decline further but at a slower pace, with an anticipated CARC of -0.7% for the five-year period 2015 - 2020, which is expected to drive the market to a value of $4.8bn by the end of 2020.